NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.
In this episode, Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.
In a wide ranging discussion, with Lazurite Co-Founder/CEO Eugene Malinskiy, we learn more about the origins of the company, it's current status, and get...
David Yakobi, MD is a Board Certified Cardiac Surgeon and specialist in Cardiology, Intensive Care, Emergency Medicine, Hemodynamics, and Physiology. Dr. Yakobi has vast...
Matt Patsky is CEO and Lead Portfolio Manager of the Trillium ESG Global Equity strategy and Portfolio Manager of the Trillium Sustainable Opportunities strategy....
